Dr. McGlynn exited Merck this past summer, rather abruptly. Though to be fair, the level of uncertainty about post-merger/bust-up seating arrangements likely contributed to her decision to move proactively. This comes from the PR Newswires:
. . . .Amicus Therapeutics today announced the appointment of Margaret G. McGlynn, R.Ph., to its Board of Directors. Ms. McGlynn most recently served as President of Vaccines and Infectious Diseases for Merck & Co., Inc. . . .
. . . .Amicus Therapeutics is a late-stage biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Amicus is initially targeting lysosomal storage disorders and diseases of neurodegeneration with unmet medical needs.